Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2023 | MinimuMM-seq: a novel, minimally invasive approach to characterize myeloma pathology

Irene Ghobrial • 11 May 2023
COMy 2023
Multiple Myeloma

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses a novel approach being explored to characterize multiple myeloma pathology, known as MinimuMM-seq. This minimally invasive approach provides details using whole-genome sequencing (WGS) without the need for bone marrow biopsy. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Irene Ghobrial

0:52
Using spatial proteomics to analyze the bone marrow microenvironment in SMM treated with nivolumab
Irene Ghobrial • 7 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
Early interception in SMM & novel agents being explored
Irene Ghobrial et al. • 25 Mar 2024
1:19
Single-cell sequencing of circulating tumor cells to predict progression from MGUS/SMM
Irene Ghobrial • 11 Dec 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals